Q4 Earnings Estimate for Altimmune Issued By HC Wainwright

Altimmune, Inc. (NASDAQ:ALT) – Equities research analysts at HC Wainwright issued their Q4 2027 earnings estimates for Altimmune in a research report issued to clients and investors on Monday, March 16th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.30) per share for the quarter. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%.

ALT has been the subject of a number of other reports. B. Riley Financial cut their price target on Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a report on Friday, March 6th. Barclays started coverage on shares of Altimmune in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. William Blair reiterated a “market perform” rating on shares of Altimmune in a research note on Thursday, March 5th. Finally, Wall Street Zen downgraded shares of Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $19.20.

Altimmune Price Performance

NASDAQ ALT opened at $3.62 on Tuesday. The stock has a 50-day simple moving average of $4.49 and a 200 day simple moving average of $4.30. Altimmune has a twelve month low of $2.90 and a twelve month high of $7.73. The stock has a market capitalization of $470.85 million, a PE ratio of -3.58 and a beta of 0.13. The company has a debt-to-equity ratio of 0.15, a quick ratio of 18.55 and a current ratio of 18.55.

Institutional Investors Weigh In On Altimmune

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in shares of Altimmune by 13.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after buying an additional 228,995 shares in the last quarter. Brown Wealth Management LLC boosted its position in shares of Altimmune by 131.0% during the 2nd quarter. Brown Wealth Management LLC now owns 231,083 shares of the company’s stock valued at $894,000 after acquiring an additional 131,059 shares in the last quarter. Intech Investment Management LLC increased its stake in Altimmune by 102.9% in the second quarter. Intech Investment Management LLC now owns 144,890 shares of the company’s stock valued at $561,000 after acquiring an additional 73,482 shares during the period. Jefferies Financial Group Inc. raised its position in Altimmune by 40.0% in the second quarter. Jefferies Financial Group Inc. now owns 35,000 shares of the company’s stock worth $135,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC raised its position in Altimmune by 43.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 213,384 shares of the company’s stock worth $826,000 after purchasing an additional 64,175 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Insider Buying and Selling

In other news, CEO Jerome Benedict Durso acquired 20,000 shares of the stock in a transaction dated Friday, March 6th. The shares were acquired at an average cost of $3.54 per share, for a total transaction of $70,800.00. Following the completion of the transaction, the chief executive officer owned 32,500 shares in the company, valued at approximately $115,050. This trade represents a 160.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director John Gill bought 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average price of $4.10 per share, with a total value of $51,250.00. Following the completion of the purchase, the director directly owned 12,500 shares of the company’s stock, valued at $51,250. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 55,527 shares of company stock valued at $213,778 in the last quarter. Corporate insiders own 4.40% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.